Read by QxMD icon Read

Current Therapeutic Research, Clinical and Experimental

Azadeh Nazari, Shahram Naderi Mazjin, Mansour Shamsipour
Tramadol abuse is a critical and growing health concern in Asia. In Iran, tramadol abuse arises most commonly as a result of self-medicating that leads to tramadol dependence. Buprenorphine, a partial agonist of mu opioid receptors approved for the treatment of tramadol dependence, is administered sublingually due to its extensive first-pass metabolism and resulting low oral bioavailability. A 50-year-old man presenting with tramadol dependence after self-medicating for chronic low back pain experienced adverse reactions to a minimal dosage (0...
2019: Current Therapeutic Research, Clinical and Experimental
George O Adjei, Seth K Amponsah, Bamenla Q Goka, Christabel Enweronu-Laryea, Lorna Renner, Abdul Malik Sulley, Michael Alifrangis, Jorgen A L Kurtzhals
Background: There is limited information on the safety or efficacy of currently recommended antimalarial drugs in patients with sickle cell disease (SCD), a population predisposed to worse outcomes if affected by acute malaria. Artesunate-amodiaquine (ASAQ) is the first-line treatment for uncomplicated malaria (UM) in many malaria-endemic countries and is also used for treatment of UM in SCD patients. There is, however, no information to date, on the pharmacokinetics (PK) of amodiaquine or artesunate or the metabolites of these drugs in SCD patients...
2019: Current Therapeutic Research, Clinical and Experimental
Marieke J H Coenen, Aimée D C Paulussen, Marc Breuer, Martijn Lindhout, Demis C J Tserpelis, Anja Steyls, Jörgen Bierau, Bianca J C van den Bosch
Objective: Fluoropyrimidine treatment can be optimized based on dihydropyrimidine dehydrogenase (DPD) activity. DPD dysfunction leads to increased exposure to active metabolites, which can result in severe or even fatal toxicity. Methods: We provide an overview of 8 years of DPD diagnostic testing (n = 1194). Results: Within the study period, our diagnostic test evolved from a single-enzyme measurement using first a radiochemical and then a nonradiochemical assay by ultra HPLC-MS in peripheral blood mononuclear cells with uracil, to a combined enzymatic and genetic test (ie, polymerase chain reaction) followed by Sanger sequence analysis of 4 variants of the DPYD gene (ie, DPYD*2A, DPYD*13, c...
2019: Current Therapeutic Research, Clinical and Experimental
Diego Bellido, Pablo Abellán, José Manuel Ruiz Palomar, Rogelio Álvarez Sintes, Andreu Nubiolae, Virginia Bellido, Gracia Romero
Background: Basal insulin reduces fasting blood glucose levels, but postprandial blood glucose levels may remain higher. Traditional strategies with rapid insulin intensification can cause hypoglycemic episodes and weight gain. Glucagon-like peptide-1 receptor agonists, such as the short-acting lixisenatide, are able to control postprandial excursions, without weight gain, and with a low risk of hypoglycemic events. Objective: Due to the limited data on the combination of lixisenatide with basal insulin (with or without oral antidiabetes drugs) in clinical practice, this study evaluated changes in parameters associated with glycemic control and anthropometric data after 24 weeks of this therapy intensification...
2018: Current Therapeutic Research, Clinical and Experimental
Shanna C Trenaman, Barbara J Hill-Taylor, Kara J Matheson, David M Gardner, Ingrid S Sketris
Purpose: Despite well-established concerns regarding adverse drug effects, antipsychotics are frequently prescribed for older adults. Our first objective was to identify trends in antipsychotic dispensations to older Nova Scotians. STOPP (Screening Tool of Older Persons' Potentially Inappropriate Prescriptions) criteria identify antipsychotic use in those with a history of falls as potentially inappropriate. Our second objective was to identify trends, predictors, and adherence with this STOPP criteria by identifying continued antipsychotic dispensations following a fall-related hospitalization...
2018: Current Therapeutic Research, Clinical and Experimental
Masahiro Yasaka, Andres Brainsky, Peijin Zhang, Shigeki Kushimoto
Background: Four-factor prothrombin complex concentrates (4F-PCCs) have been approved for urgent vitamin K antagonist reversal in Western countries for many years. Ethnicity and genetic variations between populations may influence the pharmacokinetic profile of 4F-PCC treatments. Objective: To report plasma levels of vitamin K-dependent coagulation factors and proteins C and S in Japanese patients following administration of a 4F-PCC approved recently in Japan. Methods: This was a subanalysis of a prospective, open-label, Phase IIIb study in Japanese patients requiring rapid vitamin K antagonist reversal owing to major bleeding (n = 6) or need for urgent surgery (n = 5)...
2018: Current Therapeutic Research, Clinical and Experimental
Dominique Baron, Christian Flin, Jérôme Porterie, Jacques Despaux, Patrice Vincent
Introduction: La viscosupplémentation du liquide synovial par injection intra-articulaire d'acide hyaluronique est un traitement symptomatique de l'arthrose, largement utilisé dans la gonarthrose (arthrose du genou). À côté des produits conçus pour être administrés par injections multiples (typiquement 3 à 5 injections à intervalles de 1 semaine), un intérêt particulier se porte sur produits en injection unique (mono-injection) qui offrent des avantages spécifiques tels que la réduction du nombre de visites au médecin et du nombre d'interventions invasives avec leurs risques associés...
2018: Current Therapeutic Research, Clinical and Experimental
Ulf Bergström, Stefan Jovinge, Jerker Persson, Lennart T H Jacobsson, Carl Turesson
Background: Treatment with tumor necrosis factor inhibitors for rheumatoid arthritis has been associated with a decreased risk of cardiovascular disease in observational studies. There are conflicting data on the influence of tumor necrosis factor inhibitors on lipid levels. Objectives: To evaluate the effect of treatment with adalimumab on blood lipid levels, lipoproteins, and atherosclerosis of the carotid artery. Methods: Fourteen patients with active rheumatoid arthritis (11 women and 3 men; mean age 63...
2018: Current Therapeutic Research, Clinical and Experimental
Anne H Neddermeyer, Kjell Hultenby, Maruthibabu Paidikondala, Ryan M Schuchman, Mehdi R M Bidokhti
Background: Research on the biogenesis of tick-borne encephalitis virus (TBEV) would benefit gene therapy. Due to specific arrangements of genes along the TBEV genome, its viral-like particles (VLPs) could be exploited as shuttles to deliver their replicon, which carries therapeutic genes, to immune system cells. Objective: To develop a flaviviral vector for gene delivery as a part of gene therapy research that can be expressed in secretable VLP suicidal shuttles and provide abundant unique molecular and structural data supporting this gene therapy concept...
2018: Current Therapeutic Research, Clinical and Experimental
Dominique Baron, Christian Flin, Jérôme Porterie, Jacques Despaux, Patrice Vincent
Background: Viscosupplementation of the synovial liquid, by intra-articular injection of hyaluronic acid, is a widely used symptomatic treatment in knee osteoarthritis. Besides products designed for multi-injections (typically 3-5 injections at 1-week intervals), special interest is being given to single-injection products that offer specific advantages such as the reduction of the number of visits to the doctor and the number of invasive interventions with their associated risks. However, a question remains about the efficacy of these monoinjections, compared with the multi-injections regimens...
2018: Current Therapeutic Research, Clinical and Experimental
Yoshikazu Kinoshita, Motoyasu Kusano, Katsuhiko Iwakiri, Mitsuhiro Fujishiro, Naoto Tachikawa, Ken Haruma
Background: The metabolism of many proton pump inhibitors is influenced by CYP2C19 genotype, which is a limitation of their use. Objectives: To determine the efficacy and safety profile of Z-215 (azeloprazole sodium) as initial treatment for reflux esophagitis (RE), dose response, and optimal dose compared with rabeprazole sodium (RPZ). Methods: We conducted an exploratory, multicenter, randomized, double-blind, parallel-group study in Japan...
2018: Current Therapeutic Research, Clinical and Experimental
Roya Abolfazli, Shirin Pournourmohammadi, Ahmadreza Shamshiri, Sara Samadzadeh
Background: The aim of this study was to evaluate the safety, tolerability, and efficacy of a brand-generic glatiramer acetate product in patients with relapsing-remitting multiple sclerosis over a 12-month period. A noninterventional cohort study was conducted on 185 patients. The patients had a confirmed and documented diagnosis of relapsing-remitting multiple sclerosis as defined by the Revised McDonald Criteria (2010), were ambulatory with a Kurtzke Expanded Disability Status Scale score of 0 to 5...
2018: Current Therapeutic Research, Clinical and Experimental
George Bouboulis, Vasileios G Bonatsos, Ageliki I Katsarou, Andreas Karameris, Antonis Galanos, Argyro Zacharioudaki, George Theodoropoulos, George Zografos, Apostolos E Papalois, Konstantinos Toutouzas
Background: The protective potential of lazaroids has been reported in previous studies on ischemia/reperfusion and induced hemorrhagic shock protocols. Objectives: The present study is the first experimental protocol on the effects of the antioxidant factor U-74389G on the small intestine of swine models in a hemorrhagic shock protocol and resuscitation with 3 different types of fluids. Methods: The study included 49 Landrace breed swine that were divided into groups of 7 each...
2018: Current Therapeutic Research, Clinical and Experimental
Petr Arenberger, Monika Arenbergerova, Marie Hladíková, Simona Holcova, Bertram Ottillinger
Background and objectives: This controlled single-blind trial compared the efficacy of a lip balm with propolis special extract GH 2002 at a concentration of 0.5% in the treatment of episodes of herpes labialis with that of 5% aciclovir cream. Methods: Patients in the erythematous/papular stage were randomized: 189 patients were treated with propolis cream, 190 patients were treated with aciclovir cream (intention-to-treat population). Application was 5 times daily...
2018: Current Therapeutic Research, Clinical and Experimental
Maya Tannoury, Zouhair Attieh
Emerging markets represent an exceptional opportunity for the pharmaceutical industry. Although a precise definition is not yet available, economists define emerging markets as developing prosperous countries in which investment is expected to result in higher income despite high risks. Qualifying a market as emerging is not merely based on the economic status of the country, but also on several criteria that render the definition applicable to each country. Jim O'Neil, retired chairman of asset management at Goldman Sachs, identified leading economies of emerging markets: Brazil, Russia, India, and China (BRIC) and later Brazil, Russia, India, China, and South Africa (BRICS) and then Mexico, Indonesia, South Korea, and Turkey (MIST), which followed years later as the second tier of nations...
2017: Current Therapeutic Research, Clinical and Experimental
S Ibeneme, G Eni, A Ezuma, G Fortwengel
Background: The most important attribute to which all human beings aspire is good health because it enables us to undertake different forms of activities of daily living. The emergence of scientific knowledge in Western societies has enabled scientists to explore and define several parameters of health by drawing boundaries around factors that are known to influence the attainment of good health. For example, the World Health Organization defined health by taking physical and psychological factors into consideration...
2017: Current Therapeutic Research, Clinical and Experimental
Evangelos D Protopapadakis
Purpose: I will discuss the prospect of pharmaceutically enhancing human morality and decision making in such a way as to eliminate morally unjustifiable choices and promote desirable ones. Background: Our species in the relatively short period since it has emerged has enormously advanced in knowledge, science, and technical progress. When it comes to moral development, the distance it has covered is almost negligible. What if we could medically accelerate our moral development? What if we could once and for all render our species totally immune to certain vices? Methodology: I will examine whether pharmaceutically intervening in human morality would compromise the autonomy of moral agents...
2017: Current Therapeutic Research, Clinical and Experimental
Vanessa Strüver
Objectives: The aim was to identify theoretically expected as well as actually reported benefits from drug development and the importance of individual patient benefits compared to the collective benefits to society in general. Background: Ethical guidelines require that clinical research involving humans offer the potential for benefit. A number of characteristics can be applied to define research benefit. Often benefit is categorized as being either direct or indirect...
2017: Current Therapeutic Research, Clinical and Experimental
Gerhard Fortwengel
No abstract text is available yet for this article.
2017: Current Therapeutic Research, Clinical and Experimental
Aristides L Garcia Herrera
No abstract text is available yet for this article.
2017: Current Therapeutic Research, Clinical and Experimental
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"